[Home ] [Archive]    
:: Home :: About Journal :: Registration :: Article Submission :: Contact us :: Site Map ::
:: Volume 2, Issue 2 (Winter 2010) ::
IJBC 2010, 2(2): 77-80 Back to browse issues page
Current Treatment Strategy in Langerhans Cell Histiocytosis
Abstract:   (4770 Views)

Langerhans cell histiocytosis (LCH) is a rare disorder described as three different entities including eosinophilic granuloma
of bone, the Hand-Schuller-Christian syndrome, and Letterer-Siwe disease. LCH is currently classified into single
system LCH, and multisystem LCH. Patients with single system LCH have an excellent prognosis, and are mostly
treated with local therapy. Multisystem LCH is subdivided into low risk and high risk groups. A 6-week course of
PRED/VBL is recommended for all patients with MS-LCH. Further therapy depends on the response to the initial
course, and risk group of the patient.

Keywords: Histiocytosis, Langerhans cell histiocytosis, Treatment
Full-Text [PDF 516 kb]   (2375 Downloads)    
: Research | Subject: Pediatric Hematology & Oncology
Received: 2011/03/12
Add your comments about this article
Your username or Email:

CAPTCHA code


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Current Treatment Strategy in Langerhans Cell Histiocytosis. IJBC. 2010; 2 (2) :77-80
URL: http://ijbc.ir/article-1-177-en.html


Volume 2, Issue 2 (Winter 2010) Back to browse issues page
مجله ی خون و سرطان ایران Iranian Journal of Blood and Cancer
Persian site map - English site map - Created in 0.06 seconds with 31 queries by YEKTAWEB 3752